NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference
Results of the NBRST Trial Using Agendia’s BluePrint 80-Gene Molecular Subtyping Assay Presented IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, said new Read More
Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test
FDA Decision Covers Use of MammaPrint in FFPE for the 70-Gene Breast Cancer Recurrence Assay IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, announced Read More
Agendia’s MammaPrint and BluePrint Tests to Be Highlighted at San Antonio Breast Cancer Symposium
Expert Symposium Panel Will Offer Insights Into How Functional Molecular Subtypes Can Better Individualize Treatment IRVINE, CA and AMSTERDAM, THE NETHERLANDS – New breast cancer research on Agendia’s MammaPrint® and BluePrint® genomic tests will be presented Read More
Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds
IRVINE, CA and AMSTERDAM – New data from an ongoing study indicates the BluePrint genomic test provides information about the molecular subtype of breast cancer that adds value beyond what can be learned from conventional IHC-FISH pathology testing. Read More
Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular diagnostic company, today announced the appointment of life science industry veteran and Agendia board member Jan H. Egberts, M.D., as CEO. He replaces David Macdonald, Read More
Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment, Study Finds
IRVINE, CA and AMSTERDAM – In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast Read More
Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment
IRVINE, CA and AMSTERDAM – In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular Read More
